All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Treatment sequencing for anemic myelofibrosis
with Jean-Jacques Kiladjian & Angela Fleischman
Monday, February 26, 2024 | 16:30 CET
This independent educational activity is supported by Bristol Myers Squibb. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
Bookmark this article
GB2064 is an investigational, potential first-in-class, oral lysyl oxidase-like 2 (LOXL2) inhibitor intended for the treatment of patients diagnosed with myelofibrosis who are ineligible, intolerant, or refractory to Janus kinase inhibitor therapy. LOXL2 plays a key role in myelofibrosis, contributing to the fibrotic progression of disease via mediation of collagen crosslinking in tissue fibrosis. Recently, topline results from the phase IIa MYLOX-1 trial (NCT04679870), investigating the safety and efficacy of GB2064, were released. We summarize the key points below.
These topline results indicate that GB2064 elicits strong antifibrotic activity and inhibition of LOXL2 in a difficult-to-treat patient population. The safety profile was considered acceptable, and AEs were manageable. Further analysis is ongoing to determine the potential of subsequent clinical trial stages.
COMFORT-I and -II trials: Post hoc analysis
We summarize the key findings from the post hoc analysis of the COMFORT-I and -II trials investigating the impact of new or worsening anemia on spleen volume response and total symptom score in patients...
ASH 2022 abstracts: What’s hot in MPN?
To help navigate the exciting content presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub Steering Committee members provided their recommendations for the top...
Subscribe to get the best content related to MPN delivered to your inbox